Novartis expands clinical program of blood pressure drug
The newly-launched studies will evaluate the organ protection potential of the first-in-class direct renin inhibitor Rasilez, known as Tekturna in the US, for the treatment of heart failure
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).